EPAS1 and nonpapillary renal cell carcinoma: HIF2α is a key target for ccRCC [2–5], and the FDA recently approved a HIF2α inhibitor, Belzutifan, which has an overall response rate of 49% in Von Hippel-Lindau (VHL) mutant ccRCC [6].